Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently made a noteworthy stock transaction. According to a recent SEC filing, Lyssikatos sold 5,000 shares of the company’s common stock on May 19, 2025. The shares were sold at a weighted average price of $16.31, resulting in total proceeds of approximately $81,533. The transaction comes as the stock has fallen nearly 15% in the past week, with the current share price at $16.93. InvestingPro analysis indicates the company, valued at $835 million, maintains a Fair Value that suggests slight undervaluation.
This transaction was conducted under a Rule 10b5-1 trading plan, which Lyssikatos adopted on November 15, 2024. Following this sale, Lyssikatos still holds 985,188 shares indirectly through The Lyssikatos Revocable Trust, for which he serves as trustee. The shares were sold in multiple trades at prices ranging from $16.00 to $16.90. Notably, InvestingPro data shows analyst targets ranging from $27 to $45, suggesting significant potential upside. Subscribers can access 7 additional InvestingPro Tips and comprehensive financial metrics for deeper insight into ELVN’s investment potential.
In other recent news, Enliven Therapeutics has reported its first-quarter results, revealing a net loss of $0.57 per share, aligning with analysts’ predictions. The company’s research and development expenses totaled $24.9 million, while selling, general, and administrative expenses were $6.8 million, slightly exceeding H.C. Wainwright’s estimates. Enliven Therapeutics ended the quarter with $289.6 million in cash and equivalents, expected to support operations through late 2027. Analyst Robert Burns from H.C. Wainwright raised the company’s stock target to $40, maintaining a Buy rating, while BTIG’s Justin Zelin increased the target to $45, also with a Buy rating, following a review of promising Phase I data for ELVN-001. The company shared positive results from its ENABLE Phase 1 trial of ELVN-001 for chronic myeloid leukemia, with 44% of evaluable patients achieving a major molecular response. Enliven Therapeutics is shifting its focus to ELVN-001, planning a pivotal trial in 2026, and seeking strategic alternatives for its HER2 TKI program, ELVN-002. The safety profile of ELVN-001 was favorable, with low rates of dose interruptions and reductions, and the maximum tolerated dose was not reached.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.